NPEPPS is a novel and druggable driver of platinum resistance
R. T. Jones, M. Scholtes, A. Goodspeed, M. M. Akbarzadeh, S. Mohapatra, L. E. Feldman, H. Vekony, A. Jean, C. B. Tilton, M. V. Orman, S. Romal, C. Deiter, T. W. Kan, N. Xander, S. Araki, , J. C. Costello
This study identifies NPEPPS as a driver of cisplatin resistance in bladder cancer and shows its inhibition can enhance cisplatin efficacy in preclinical models.
bioRxiv · Mar 4, 2021 · PreprintCancer Biology